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Plasma cholesteryl ester transfer protein (CETP) catalyzes the transfer of CEs from high-density
lipoproteins (HDLs) to triglyceride-rich and low-density lipoproteins (LDLs). The hypothesis that
CETP inhibition will prevent cardiovascular disease (CVD) was based on the fact that low activity
increases HDL cholesterol and decreases LDL cholesterol. Early reports that CETP gene transfer
increased atherosclerosis in mice, and that CETP inhibition reduced lesions in cholesterol-fed
rabbits fuelled enthusiasm for the approach. Although some cautioned that the development of
CETP inhibitors was premature owing to uncertainties about their impact on the remodeling
of HDLs and reverse cholesterol transport (RCT) in humans (Fielding and Havel, 1996), drug
discovery programmes proceeded. Two parallel research tracks then emerged. While industry
progressed to clinical studies, academics sought to clarify the relations of CETP activity to RCT and
atherosclerosis. Two drugs reached Phase 3 clinical trials. However, ILLUMINATE was terminated
when torcetrapib was found to have had increased CVD. Five years later, Dal-OUTCOMES was
aborted when it was evident dalcetrapib was not conferring any benefit.
After reviewing the literature up to May 2014, Miller (2014) concluded that CETP inhibition
is more likely to increase CVD than prevent it, and was of the opinion that ongoing trials should
be stopped. Since then several further pertinent studies have been published. They include four
meta-analyses of the Taq1B polymorphism of the CETP gene. Cao et al. (2014) concluded that
B2B2 homozygotes (low CETP activity, high HDL cholesterol) have a lower risk of myocardial
infarction (MI) than B1B1 subjects. Using Mendelian randomization, Wu et al. (2014) found the
B2 allele to be associated with a lower risk of coronary heart disease (CHD). However, another
Mendelian randomization (Niu and Qi, 2015) found the B2 allele to be associated with a higher risk
of CVD than the B1 allele. In this context, an earlier meta-analysis by Dullaart and Sluiter (2008)
is of interest. These authors found that B2B2 carriers were less frequent among cases drawn from
samples at high CVD risk than among cases drawn from population-based samples. Furthermore,
in the latter case the odds ratio for CVD was 1.45 (95% CI: 1.07–1.95) in B2B2 relative to B1B1,
while in the former it was 0.84 (0.74–0.96), suggesting that in the general population the B2 allele is
actually associated with higher CVD risk in spite of the higher HDL cholesterol. Regieli et al. (2008)
had come to a similar conclusion in the REGRESS study. After following 812 men with CHD on
statins for 10 years, the B2 allele was associated with a hazard ratio for CVD death of 1.59 (P = 0.01)
despite the expected low CETP activity and high HDL cholesterol.
Four additional meta-analyses looked at the impact of CETP inhibitors on CVD risk as part
of larger studies of the effects of HDL cholesterol-raising agents in patients taking statins. All
four concluded that the trials have not demonstrated a beneficial effect (Keene et al., 2014;
Hourcade-Potelleret et al., 2015; Ip et al., 2015; Verdoia et al., 2015). In clinical studies, Gu et al.
(2014) reported that although the A allele of the −629◦C/A polymorphism of the CETP gene
was associated with a lower plasma CETP concentration than the C allele, it had not reduced
CVD events in patients taking atorvastatin. Kastelein et al. (2015) observed no significant effect of
anacetrapib on CVD incidence (four events vs. zero in the treated and placebo groups, respectively)
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during 12 months of follow-up in patients with heterozygous
familial hypercholesterolemia already on lipid-lowering
treatment. Scharnagl et al. (2014) confirmed earlier reports that
human plasma samples with low CETP concentrations were
less effective in promoting cholesterol eﬄux from cultured
macrophages than samples with high concentrations. In animal
studies, Kühnast et al. (2015) found that anacetrapib reduced
atherosclerosis in APOE*3Leiden.CETP transgenic mice. Briand
et al. (2014) compared anacetrapib with dalcetrapib in hamsters,
a species with natural CETP. In normal animals, neither drug at
doses equipotent for CETP inhibition (by 60%) had any effect on
macrophage-to-feces RCT, although they did lower equally the
fractional clearance rate of HDL-CE. In dyslipidaemic animals,
anacetrapib increased RCT, whereas an equipotent dose of
dalcetrapib reduced it. Liu et al. (2015) found that inhibition
of DNA topoisomerase II (Topo II) by etoposide, tenipooside
or Topo II siRNA increased CETP gene expression and CETP
secretion in HepG2 cells. When given to CETP transgenic mice,
teniposide induced CETP expression in the liver, and increased
macrophage-to-feces RCT to a greater degree than in wild-type
mice with no CETP. Using a computer model of lipoprotein
metabolism to analyze the on/off kinetics of the short-acting
potent CETP inhibitor RG7232, Lu et al. (2015) concluded that
inhibition of CETP is likely to reduce prebeta HDL production
in humans.
During the past 25 years, lipidologists have become
accustomed to the controversies in this field. While the
decrease in LDL cholesterol has been assumed to be beneficial,
the rise in HDL cholesterol has long prompted discussion on
three fronts. First, the early concerns (Fielding and Havel, 1996)
that HDL remodeling might be deranged, leading to lowered
prebeta HDL production, have not been allayed. Second, the early
assumption that the rise in HDL CE would increase the direct
delivery of CEs to the liver via SR-B1 receptors was challenged by
evidence that the receptors may be saturated at normal plasma
HDL concentrations (Woollett and Spady, 1997; Nieland et al.,
2011). Third, evidence was reported that the large CE-rich HDLs
produced by CETP inhibition might be dysfunctional. Despite
these concerns, momentum was maintained in the hope that the
reduction of LDL would more than offset any adverse effects on
HDL. However, as time has gone on the cumulative evidence
has increasingly pointed to CETP having both a facilitative role
in RCT and a net preventative effect on CVD. The recent work
summarized above has not weakened this evidence.
Although the debate has centered largely on whether CETP
inhibition is likely to have a beneficial or detrimental impact
on CVD, the possibility that the net effect of the combined
changes in LDL and HDL metabolism might vary according to
the prevailing physiologic conditions, and therefore from subject
to subject, and from time to time in the same subject, also merits
consideration. Being at a crossroad in the transport of lipids, and
having multiple effects on lipoprotein metabolism, the overall
effects of CETP activity and its inhibitionmight vary according to
the ambient HDL and LDL particle concentrations, for example,
or to interplay with other genes. Reports of interactions between
CETP alleles and alleles of the lipoprotein lipase (Corsetti et al.,
2011), hepatic lipase (Soyal et al., 2011), apolipoprotein E (Sun
et al., 2014), and nitric oxide synthase (Rahimi et al., 2012) genes
seem to add weight to this possibility.
It remains that the tandem hypotheses that CETP inhibition
will both enhance RCT and prevent CVD are without sound
scientific bases. Indeed a growing body of evidence of three
kinds now supports the contrary. First, in three out of three
experimental studies of their type, macrophage-to-feces RCT
in vivo was increased when CETP expression was enhanced
(Briand et al., 2014; Miller, 2014). Second, each of five studies
that examined the effect of CETP activity in human plasma on
cholesterol eﬄux from cultured cells in vitro found that high
activity plasma was more effective than low activity (Miller, 2014;
Scharnagl et al., 2014). Third, each of six prospective cohort
observational studies have found that CETP concentration or
activity was related inversely to CVD incidence (Miller, 2014).
In the author’s opinion, this is sufficient to justify stopping
all ongoing clinical trials of CETP inhibitors. Carrying on and
hoping for the best, while participants are unaware of the
evolving evidence base, is not acceptable.
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